InChI
1S/C22H43N5O13.H2O4S/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21;1-5(2,3)4/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36);(H2,1,2,3,4)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+;/m0./s1
InChI key
HIBICIOPDUTNRR-XTHCGPPUSA-N
SMILES string
O=C([C@@H](O)CCN)N[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O[C@@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O3)[C@@H](N)C1.O=S(O)(O)=O.[F,Cl,Br,I]
Quality Level
form
liquid, ready-to-use solution
specific activity
Antibacterial
concentration
25 mg/mL in water
antibiotic activity spectrum
Gram-negative bacteria, Gram-positive bacteria, mycobacteria
mode of action
protein synthesis | interferes
storage temp.
2-8°C
General description
Amikacin is semisynthetic aminoglycoside antibiotic derived from kanamycin A. Amikacin has broad spectrum activity against serious gram-negative bacilli drug resistant infections and also mycobacteria type infections. Amikacin binds to 30S bacterial ribosomal subunit causing a change of conformation, thus disrupting mRNA’s interaction with tRNA and hampering bacterial growth. Amikacin also showed potency against some gram-positive bacteria like methicillin-resistant Staphylococcus aureus (MRSA). Amikacin is extensively used for multidrug resistant tuberculosis treatment with 1ug/mL MIC value against Mycobacterium tuberculosis. Additionally, Amikacin MIC studies of gram negative and gram positive bacteria showed MIC distribution range of 0.094-48µg/ml. Several other studies showed that Amikacin has a synergistic effect combined with β-lactams against methicillin-resistant Staphylococcus spp. strains and Pseudomonas aeruginosa. Amikacin is additionally used for wound healing assays at concentration of 250 µg/mL.
Other Notes
The suggested concentration of Amikacin for assays is 0.094-250 µg/mL therefore, it is recommended to dilute the ready made solution 1:100-266,000. Amikacin:Sulfate ratio 1:1.8
signalword
Warning
hcodes
Hazard Classifications
Skin Sens. 1
存储类别
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
涉药品监管产品
此项目有
BB-K 8, a new semisynthetic aminoglycoside antibiotic.
H Kawaguchi et al.
The Journal of antibiotics, 25(12), 695-708 (1972-12-01)
Sergei B Vakulenko et al.
Clinical microbiology reviews, 16(3), 430-450 (2003-07-15)
Aminoglycoside antibiotics have had a major impact on our ability to treat bacterial infections for the past half century. Whereas the interest in these versatile antibiotics continues to be high, their clinical utility has been compromised by widespread instances of
Maria S Ramirez et al.
Molecules (Basel, Switzerland), 22(12) (2017-12-20)
Aminoglycosides are a group of antibiotics used since the 1940s to primarily treat a broad spectrum of bacterial infections. The primary resistance mechanism against these antibiotics is enzymatic modification by aminoglycoside-modifying enzymes that are divided into acetyl-transferases, phosphotransferases, and nucleotidyltransferases.
Henri Sueke et al.
Investigative ophthalmology & visual science, 51(5), 2519-2524 (2009-12-19)
To determine the minimum inhibitory concentrations (MICs) of 12 antimicrobials in current ophthalmic use and 4 potentially new alternatives against isolates from bacterial keratitis. Bacteria were collected from cases of bacterial keratitis in six centers in the United Kingdom between
Yun-Hsin Wang et al.
Toxics, 8(4) (2020-11-26)
(1) Background: Amikacin is an aminoglycoside antibiotic used for treating gram-negative bacterial infections in cancer patients. In this study, our aims are to investigate the migratory inhibition effects of amikacin in human MDA-MB-231 cells. (2) Methods: We used a wound-healing
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持